Bio-Rad Laboratories (BIO) to Release Quarterly Earnings on Tuesday

Bio-Rad Laboratories (NYSE:BIO) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $2.04 per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share for the quarter, topping analysts’ consensus estimates of $2.93 by $0.17. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The business had revenue of $681.18 million for the quarter, compared to analysts’ expectations of $685.00 million. During the same period in the prior year, the company posted $3.31 EPS. The business’s revenue for the quarter was down 6.7% on a year-over-year basis. On average, analysts expect Bio-Rad Laboratories to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Bio-Rad Laboratories Trading Up 0.2 %

Shares of BIO opened at $279.83 on Monday. Bio-Rad Laboratories has a twelve month low of $261.59 and a twelve month high of $468.45. The company has a current ratio of 5.83, a quick ratio of 4.34 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $7.98 billion, a P/E ratio of -13.02 and a beta of 0.94. The firm’s 50-day moving average is $318.52 and its two-hundred day moving average is $314.71.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. UBS Group lifted their price objective on Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Citigroup lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $400.00 to $365.00 in a research report on Wednesday, April 3rd. Royal Bank of Canada dropped their target price on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a report on Friday, February 16th. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $468.00.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP Michael Crowley sold 3,000 shares of Bio-Rad Laboratories stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the completion of the sale, the executive vice president now directly owns 6,942 shares in the company, valued at $2,332,512. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 17.06% of the stock is owned by insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.